The Yale Cancer Center Consortium to Advance Equity in Early Phase Clinical Trials
The Yale Cancer Center Consortium to Advance Equity in Early Phase Clinical Trials is a multi-year, multidisciplinary membership opportunity comprised of leading pharmaceutical and biotechnology companies, philanthropic stakeholders, and community leaders working hand-in-hand with Yale clinician-scientists to advance a novel model for clinical trial participation. As this initiative has untapped potential to improve state-of-art accessibility to early phase cancer clinical trials across industry and academic sectors, Yale Cancer Center is seeking a plurality of corporate members for this initiative, which is not exclusive to a single party.
The Consortium has three pillar aims:
- To conduct a multi-level assessment of the unique facilitators and barriers to recruitment of under-represented minority (URM) populations to early phase (Phase Ia/Ib/I with expansion cohorts/limited Phase II) cancer clinical trials, addressing patient, provider, health system, and policy-level influences.
- To implement a sustainable hybrid decentralization clinical trials model which will:
- Increase recruitment of URM patients to early phase oncology clinical trials
- Maintain patient safety and data integrity of early phase clinical trials
- To evaluate the patient, provider, and health system experience of the hybrid decentralization model and assess its ability to address barriers to early phase trial inclusion of URM patients.
For more information:
Associate Cancer Center Director for Experimental Therapeutics
Senior Associate Director, Corporate and Foundation Relations